Acacia Communications, Inc. (ACIA) Reaches $33.62 After 7.00% Up Move; Eleven Biotherapeutics (EBIO)’s Sentiment Is 2.25

May 27, 2018 - By Adrian Mccoy

The stock of Acacia Communications, Inc. (NASDAQ:ACIA) is a huge mover today! The stock increased 4.44% or $1.43 during the last trading session, reaching $33.62. About 1.42M shares traded or 24.73% up from the average. Acacia Communications, Inc. (NASDAQ:ACIA) has declined 30.95% since May 27, 2017 and is downtrending. It has underperformed by 42.50% the S&P500.The move comes after 5 months positive chart setup for the $1.35B company. It was reported on May, 27 by Barchart.com. We have $35.97 PT which if reached, will make NASDAQ:ACIA worth $94.50M more.

Eleven Biotherapeutics (EBIO) investors sentiment increased to 2.25 in Q4 2017. It’s up 1.70, from 0.55 in 2017Q3. The ratio is more positive, as 9 hedge funds increased and started new positions, while 4 sold and trimmed equity positions in Eleven Biotherapeutics. The hedge funds in our database now own: 1.80 million shares, up from 1.21 million shares in 2017Q3. Also, the number of hedge funds holding Eleven Biotherapeutics in top ten positions was flat from 0 to 0 for the same number . Sold All: 2 Reduced: 2 Increased: 5 New Position: 4.

More notable recent Acacia Communications, Inc. (NASDAQ:ACIA) news were published by: Seekingalpha.com which released: “Acacia Hit By ZTE Ban” on May 07, 2018, also Streetinsider.com with their article: “UPDATE: NXP Semiconductors (NXPI), Acacia (ACIA) Trade Higher On Reports of ZTE Deal” published on May 25, 2018, Globenewswire.com published: “Acacia Communications Announces Stock Repurchase Program” on May 02, 2018. More interesting news about Acacia Communications, Inc. (NASDAQ:ACIA) were released by: Seekingalpha.com and their article: “NXP Semiconductors, Micron among movers on trade war hold” published on May 21, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 05/22: (PLAB) (ACIA) (AAP) Higher; (LBY) (DY) (JCP) Lower (more…)” with publication date: May 22, 2018.

Among 5 analysts covering Acacia Communications (NASDAQ:ACIA), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Acacia Communications has $125 highest and $39 lowest target. $85.50’s average target is 154.31% above currents $33.62 stock price. Acacia Communications had 9 analyst reports since June 7, 2016 according to SRatingsIntel. As per Tuesday, October 11, the company rating was maintained by Needham. The rating was initiated by Goldman Sachs with “Neutral” on Tuesday, June 7. Deutsche Bank maintained the shares of ACIA in report on Friday, September 9 with “Buy” rating. The rating was maintained by Needham on Friday, August 12 with “Buy”. The stock of Acacia Communications, Inc. (NASDAQ:ACIA) earned “Outperform” rating by Cowen & Co on Tuesday, June 7. Deutsche Bank initiated Acacia Communications, Inc. (NASDAQ:ACIA) on Tuesday, June 7 with “Buy” rating. The rating was maintained by Deutsche Bank on Thursday, July 14 with “Buy”. As per Tuesday, June 7, the company rating was initiated by Needham. Morgan Stanley initiated Acacia Communications, Inc. (NASDAQ:ACIA) on Thursday, December 8 with “Equal-Weight” rating.

Acacia Communications, Inc. develops, makes, and sells high-speed coherent optical interconnect products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. The company has market cap of $1.35 billion. The Company’s products include a series of low-power coherent digital signal processors application-specific integrated circuits and silicon photonic integrated circuits integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per second for use in long-haul, metro, and inter-data center markets. It has a 36.54 P/E ratio. The firm sells its products through a direct sales force to network equipment manufacturers.

Analysts await Acacia Communications, Inc. (NASDAQ:ACIA) to report earnings on August, 2. They expect $-0.20 EPS, down 205.26% or $0.39 from last year’s $0.19 per share. After $-0.03 actual EPS reported by Acacia Communications, Inc. for the previous quarter, Wall Street now forecasts 566.67% negative EPS growth.

The stock increased 24.15% or $0.64 during the last trading session, reaching $3.29. About 15.53M shares traded or 267.89% up from the average. Eleven Biotherapeutics, Inc. (EBIO) has declined 52.78% since May 27, 2017 and is downtrending. It has underperformed by 64.33% the S&P500.

Eleven Biotherapeutics, Inc., a biologic oncology company, focuses on the design and development of targeted protein therapeutics . The company has market cap of $157.23 million. It develops products based on its proprietary TPT platform and focused on addressing areas of unmet medical needs in cancer. It currently has negative earnings. The companyÂ’s lead product candidates include Vicinium that is in Phase 3 clinical trial in the United States and Canada for the treatment of non-muscle invasive bladder cancer; and Proxinium for use in treating squamous cell carcinoma of the head and neck.

Virtu Financial Llc holds 0.02% of its portfolio in Eleven Biotherapeutics, Inc. for 427,048 shares. Bank Of New York Mellon Corp owns 44,849 shares or 0% of their US portfolio. Moreover, Blackrock Inc. has 0% invested in the company for 445,463 shares. The Texas-based Bridgeway Capital Management Inc has invested 0% in the stock. Citadel Advisors Llc, a Illinois-based fund reported 15,372 shares.

More recent Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) news were published by: Businesswire.com which released: “Eleven Biotherapeutics Announces Corporate Name Change to Sesen Bio” on May 16, 2018. Also Nasdaq.com published the news titled: “Mid-Afternoon Market Update: Blink Charging Rises After Q1 Results; Purple Innovation Shares Slide” on May 16, 2018. Benzinga.com‘s news article titled: “Benzinga’s Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss” with publication date: May 03, 2018 was also an interesting one.

Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>